Grifols, S.A. (NASDAQ:GRFS) Stock Short Interest Report for September

Posted by Brenda Bartman on Oct 15th, 2026

Grifols, S.A. (NASDAQ:GRFS – Get Free Report) was the recipient of a significant increase in short interest during the month of September. As of September 30th, there was short interest totaling 7,001,241 shares, an increase of 105.0% from the September 15th total of 3,414,455 shares. Based on an average daily trading volume, of 808,104 shares, the days-to-cover ratio is currently 8.7 days. Currently, 1.0% of the shares of the company are short sold.

Analysts Set New Price Targets

Several analysts have commented on GRFS shares. Zacks Research raised Grifols from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. Weiss Ratings raised Grifols from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, August 17th. Finally, Wall Street Zen downgraded Grifols from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Reduce” and an average price target of $10.00.

Read Our Latest Stock Analysis on GRFS

Grifols Stock Performance

Shares of GRFS stock traded up $0.24 during mid-day trading on Thursday, hitting $7.49. The stock had a trading volume of 685,665 shares, compared to its average volume of 634,230. Grifols has a fifty-two week low of $6.96 and a fifty-two week high of $9.90. The firm has a market cap of $5.09 billion, a PE ratio of 39.39, a PEG ratio of 0.26 and a beta of 0.70. The company has a debt-to-equity ratio of 1.10, a current ratio of 2.37 and a quick ratio of 0.81. The company’s 50-day simple moving average is $7.63 and its 200-day simple moving average is $7.73.

Institutional Trading of Grifols

Hedge funds have recently modified their holdings of the business. Armistice Capital LLC increased its holdings in shares of Grifols by 23.8% in the 4th quarter. Armistice Capital LLC now owns 2,768,000 shares of the biotechnology company’s stock valued at $25,881,000 after purchasing an additional 532,000 shares in the last quarter. Flat Footed LLC boosted its holdings in Grifols by 26.5% during the first quarter. Flat Footed LLC now owns 1,372,394 shares of the biotechnology company’s stock worth $11,007,000 after buying an additional 287,867 shares in the last quarter. Tidal Investments LLC boosted its holdings in Grifols by 9.8% during the second quarter. Tidal Investments LLC now owns 1,233,082 shares of the biotechnology company’s stock worth $8,730,000 after buying an additional 109,612 shares in the last quarter. Royal Bank of Canada grew its position in Grifols by 15.4% during the first quarter. Royal Bank of Canada now owns 785,703 shares of the biotechnology company’s stock worth $6,301,000 after buying an additional 104,850 shares during the period. Finally, Hennion & Walsh Asset Management Inc. grew its position in Grifols by 13.8% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 592,173 shares of the biotechnology company’s stock worth $4,193,000 after buying an additional 72,037 shares during the period.

About Grifols

(Get Free Report)

Grifols SA is a global healthcare company based in Barcelona, Spain, and is listed on Nasdaq under the symbol GRFS. Founded in 1909, the company is primarily focused on developing, manufacturing and supplying plasma-derived medicines and other healthcare products.

Its principal therapies include immunoglobulins, albumin, alpha-1 antitrypsin and coagulation factors, which are used to treat immune deficiencies, respiratory disorders, bleeding conditions and other serious diseases. Grifols operates a network of plasma donation centers, mainly in the United States and Europe, to collect the source plasma used in its medicines.

Grifols also provides diagnostic solutions, including instruments and reagents used in blood typing, transfusion medicine and laboratory testing.